Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07776821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07776821 · ClinicalTrials.gov record · last posted 2026-08-25

An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.

StatusRecruiting
PhasePhase 4
Started2025-09-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The objective of this clinical trial is to investigate the efficacy and safety of Enlonstobart combined with concurrent chemoradiotherapy following induction chemotherapy for locally advanced cervical cancer. The primary questions it aims to address are: Can the Enlonstobart combination regimen improve the objective response rate and disease control rate in patients with locally advanced cervical cancer? What is the safety and tolerability profile of this combination regimen, and will any unexpected serious adverse events occur? Participants will: Receive induction therapy with Enlonstobart in combination with chemotherapy agents (e.g., paclitaxel plus platinum); Receive Enlonstobart in combination with concurrent chemoradiotherapy (external beam radiation therapy plus brachytherapy, with concurrent chemotherapy); Undergo regular tumor imaging evaluations (CT/MRI) and hematological safety assessments; Cooperate in completing efficacy assessments, adverse event documentation, and long-term follow-up.
Trial Details
NCT Number NCT07776821
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Collaborators: Tianjin Cancer Hospital Airport Hospital
Conditions Uterine Cervical Neoplasms
Enrollment 31 participants
Start Date 2025-09-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-25